Comment on ‘Intravitreal versus Subcutaneous Adalimumab in Active Non-Infectious Uveitis: A Randomized Non-Inferiority Trial’

Hassoun M et al. report that intravitreal adalimumab is non-inferior to subcutaneous administration for controlling intraocular inflammation in non-infectious uveitis. This correspondence discusses the broader clinical implications of these findings, highlighting cost considerations, the need to balance systemic safety with local procedural risks, and the importance of patient-reported outcomes and extended dosing regimens to enhance treatment acceptability.